FDANews
FDAnews Device Daily Bulletin

Boston Scientific’s Precision Spectra Spinal Cord Stimulator Passes Clinical Tests

Dec. 10, 2013

New data from retrospective studies indicate Boston Scientific’s Spectra spinal cord stimulator system provides significant relief from pain three months after being implanted, the company announced.

The studies show a 94 percent success rate, with patients reporting a nearly five-point reduction in pain on the 1-10 Visual Analog Scale. In patients with lower back pain specifically, the decline in pain registered 9 on the scale.

The system consists of an implantable pulse generator and lead wires that are placed in the spine via an injection. Together, the system blocks pain via the spine’s own nerve fibers, said BSX spokesman Ryan Davenport.

The IPG is adjusted for each patient, with the Illumina 3D software taking into account spinal anatomy such as dura thickness or amounts of cerebral spinal fluid. The patient controls the device via remote control, selecting pain management programs and intensity levels adequate for different levels of activity.

BSX’s Spectra system was approved by the FDA early this year and postmarketing studies are ongoing. The company also markets the device in Europe, the Middle East, Africa, Australia and other parts of the world. — Lena Freund

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.